ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
Clinical safety rating: safe
Other anticholinergic drugs can have additive effects Can cause paradoxical bronchospasm and narrow-angle glaucoma.
Albuterol sulfate is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle. Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing bronchoconstriction and mucus secretion.
| Metabolism | Albuterol is metabolized primarily by sulfation in the gut wall and liver; minor metabolism by CYP450. Ipratropium is partially metabolized by hydrolysis to inactive metabolites. |
| Excretion | Albuterol: renal excretion of unchanged drug and metabolites (~60-70% as metabolites, ~10-20% unchanged); Ipratropium: primarily renal (~50% unchanged), with biliary/fecal excretion accounting for minor amounts. |
| Half-life | Albuterol: terminal half-life 3.8-6 hours; Ipratropium: terminal half-life 1.5-4 hours (clinical: twice-daily dosing for chronic therapy). |
| Protein binding | Albuterol: ~50% bound to albumin; Ipratropium: ~0-9% bound (minimal). |
| Volume of Distribution | Albuterol: 1.0-1.5 L/kg (extensive tissue distribution); Ipratropium: 2.3-4.6 L/kg (large, due to high tissue binding). |
| Bioavailability | Inhalation: albuterol ~10-20% (lung deposition); ipratropium ~7-32% (inhaled). Oral: albuterol ~50% (not used). Ipratropium negligible oral bioavailability. |
| Onset of Action | Inhalation: 5-15 minutes for bronchodilation. |
| Duration of Action | Inhalation: 4-6 hours (albuterol component); ipratropium provides additional bronchodilation up to 6-8 hours. Clinical note: More sustained effect than albuterol alone. |
| Molecular Weight | Albuterol sulfate: 576.7 Da (for the sulfate salt); Ipratropium bromide: 412.4 Da (for the bromide salt). Combined: Not applicable. |
2 inhalations (each inhalation delivers 90 mcg albuterol sulfate and 18 mcg ipratropium bromide) four times daily via oral inhalation; maximum 12 inhalations in 24 hours.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). For severe renal impairment (eGFR <30 mL/min/1.73 m²), use with caution due to potential accumulation of ipratropium; data insufficient for specific dose adjustment. |
| Liver impairment | No specific dose adjustment recommended for Child-Pugh Class A or B. For Child-Pugh Class C (severe hepatic impairment), use with caution as systemic exposure may be increased; no formal studies available. |
| Pediatric use | For children 4-11 years: 2 inhalations four times daily as needed; not to exceed 12 inhalations in 24 hours. For children <4 years: safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended; initiate at low end of dosing range (2 inhalations four times daily) and titrate based on response and tolerability, considering renal/hepatic function and comorbidities. |
| 1st trimester | Albuterol sulfate is generally considered safe in pregnancy; ipratropium bromide has limited data but is often avoided. Use only if potential benefit justifies risk. |
| 2nd trimester | Both agents are used for asthma exacerbations; ipratropium is usually reserved for acute settings. No major teratogenic signals. |
| 3rd trimester | Beta-agonists (albuterol) may cause maternal tachycardia and hyperglycemia; may delay labor. Ipratropium has minimal systemic absorption. |
Clinical note
Other anticholinergic drugs can have additive effects Can cause paradoxical bronchospasm and narrow-angle glaucoma.
| FDA category | Animal |
| Placental transfer | Albuterol crosses placenta; extent is moderate. Ipratropium: Quaternary ammonium compound, limited placental transfer due to polarity and low bioavailability. |
■ FDA Black Box Warning
None
| Common Effects | asthma |
| Serious Effects |
Hypersensitivity to albuterol, ipratropium, or any componentHypersensitivity to atropine or its derivatives
| Precautions | Paradoxical bronchospasm, Cardiovascular effects (tachycardia, arrhythmias, hypertension), Hypersensitivity reactions, Immediate hypersensitivity reactions (urticaria, angioedema, rash), Not for acute deterioration of COPD, Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction |
| Food/Dietary | No significant food interactions. Avoid excessive caffeine intake as it may increase stimulant effects like nervousness or palpitations. |
Loading safety data…
| Breastfeeding |
| Albuterol is excreted into breast milk in small amounts; unlikely to cause adverse effects in infant. Ipratropium is not absorbed orally, so minimal risk. Monitor infant for signs of beta-adrenergic stimulation. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Inhaled beta-agonists and anticholinergics have not been associated with major congenital malformations in human studies, but animal studies with albuterol showed cleft palate and limb defects at high doses. Second/third trimester: No known increased risk; uteroplacental perfusion should be monitored as beta-agonists may cause tachycardia and hyperglycemia in the fetus. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and blood glucose during acute use. Assess fetal heart rate and uterine activity if tocolysis is used. In chronic use, monitor fetal growth and amniotic fluid volume. |
| Fertility Effects | No known adverse effects on fertility in humans. Animal studies with albuterol showed decreased fertility at high oral doses; ipratropium had no effect. |
| Clinical Pearls | Albuterol sulfate and ipratropium bromide combination is used for COPD exacerbations and asthma. Maximum bronchodilation occurs 1-2 hours after inhalation. Monitor for paradoxical bronchospasm (rare but serious). Palpitations and tachycardia may occur, especially in elderly or those with cardiac arrhythmias. Do not exceed 12 inhalations in 24 hours for the metered-dose inhaler (MDI). Can cause dry mouth and unpleasant taste; rinse mouth after use. |
| Patient Advice | Use exactly as prescribed; do not use more frequently than directed. · Rinse mouth with water after each use to prevent dry mouth and throat irritation. · Shake inhaler well before each use. · If you miss a dose, skip it and take the next at the regular time; do not double the dose. · Seek emergency care if symptoms worsen or you need more inhalations than usual. · Store at room temperature, away from heat and open flames. |